Scalable, high throughput microfluidic platforms for tissue specific biomaterials development and tissue genesis

点击翻译按钮获取中文摘要

The co-development of novel biomaterial platforms and new generation production methods for tissue analogues will provide the necessary stimulus for improved and more relevant methods of enhanced repair or regeneration of diseased or damaged tissues. These outcomes will result in faster time-to-market new generation therapeutic products for Australia and the world. These advances will have a significant impact on our healthcare costs and the quality of life for all Australians.